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The clinical course of astrocytoma grade II (AII) is highly variable and not reflected by histological characteristics. As one of the best
prognostic factors, higher age identifies rapid progressive A II. For patients over 35 years of age, an aggressive treatment is normally
propagated. For patients under 35 years, there is no clear guidance for treatment choices, and therefore also the necessity of
histopathological diagnosis is often questioned. We studied the additional prognostic value of the proliferation index and the
detection of genetic aberrations for patients with A II. The tumour samples were obtained by stereotactic biopsy or tumour resection
and divided into two age groups, that is 18–34 years (n¼19) and X35 years (n¼28). Factors tested included the proliferation
(Ki-67) index, and numerical aberrations for chromosomes 1, 7, and 10, as detected by in situ hybridisation (ISH). The results show
that age is a prognostic indicator when studied in the total patient group, with patients above 35 years showing a relatively poor
prognosis. Increased proliferation index in the presence of aneusomy appears to identify a subgroup of patients with poor prognosis
more accurately than predicted by proliferation index alone. We conclude that histologically classified cases of A II comprise a
heterogeneous group of tumours with different biological and genetic constitution, which exhibit a highly variable clinical course.
Immunostaining for Ki-67 in combination with the detection of aneusomy by ISH allows the identification of a subgroup of patients
with rapidly progressive A II. This is an extra argument not to defer stereotactic biopsy in young patients with radiological suspicion of
A II.
British Journal of Cancer (2003) 89, 128–134. doi:10.1038/sj.bjc.6601067 www.bjcancer.com
& 2003 Cancer Research UK
Keywords: astrocytoma grade II; prognosis; proliferation; aneusomy; Ki-67 index; in situ hybridisation
                                                        
Controversy exists with respect to optimal treatment protocols for low-
grade diffuse astrocytoma (astrocytoma WHO grade II; A II) because
prospective studies comparing treatment strategies are rare (Karim et al,
1996; 2002; Shaw et al, 2002). Another reason for this controversy is that
the interval after which malignant progression of A II occurs is difficult
to predict. Clinical factors that may correlate with survival include those
related to patient age, presenting symptoms, duration of symptoms,
performance status, tumour volume, extent of resection, and timing and
dose of radiotherapy (Berger et al, 1994; Lote et al, 1997). Patient age is
t h es i n g l ec o n s i s t e n tp r o g n o s t i cf a c t o ri nt h e s er e t r o s p e c t i v es t u d i e s .
Patient age under 35 years (Shaw et al, 1989; Arienti et al, 2001), or
under 40 years in other series (Bauman et al, 1999) is often associated
with a prolonged survival. Since the benefits of early treatment have to
be balanced against the possibility of long-term side effects from
radiation therapy, patient age is decisive in current treatment protocols
for A II. For patients under 35 years of age, the benefit of early and
aggressive treatment has never been proven sufficiently and therefore
treatment is often deferred (Vecht, 1993). As a result, in young patients
also a controversy exists concerning the usefulness of an immediate
histological diagnosis, involving stereotactic biopsy (Recht et al, 1992).
Ultimately the majority of A II progresses to high-grade
astrocytomas (astrocytoma WHO grade III and grade IV; A III/A
IV), which is characterised by an increase in proliferation
activity and an accumulation of genetic abnormalities. Prolifera-
tion and cytogenetic markers may therefore identify rapid
progressive A II. Increased proliferation activity correlates with
shorter survival in most series of astrocytomas, although the
number of A II was often too small for separate analyses (Sallinen
et al, 1994; Korkolopoulou et al, 1997). Numerical chromosomal
aberrations have been reported in astrocytomas, such as aneusomy
1, trisomy 7 and monosomy 10. It has been shown that trisomy 7
correlates with shorter survival of A II patients (Wessels et al,
2002).
In the underlying study, the prognostic value of the proliferation
(Ki-67) index and the detection of numerical aberrations for
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ychromosomes 1, 7, and 10 was evaluated. The correlation of ;these
parameters with survival analysis was performed for patients aged
18–34 years and X35 years to assess whether these parameters
allow the identification of rapid progressive A II in young patients.
MATERIALS AND METHODS
Patient material
Tissue specimens from 47 adult patients diagnosed with
supratentorial astrocytoma grade II were collected from the
data files of the Departments of Pathology of the University
Hospitals of Maastricht and Groningen, and the Atrium
Hospital in Heerlen, The Netherlands. Histopathological
revision according to the WHO classification (Kleihues and
Cavenee, 2000) revealed 44 fibrillary astrocytomas and three
gemistocytic astrocytomas (all WHO grade II). Astrocytomas with
mitotic figures were not included in this series. In order
to diminish the probability of sampling error A II in which
the neuroradiologists suspected high-grade astrocytoma and
which showed radiological characteristics for tumour bleeding
as well as extensive contrast enhancement, were not included
in this series. Patient records were examined with regard to
the first neurological symptoms, radiological findings, neurosur-
gical procedure, dose and timing of radiotherapy, and survival
interval.
Mean and median ages were respectively, 38 and 41 years (range,
18–69 years). The study included 22 women (47%) and 25 men
(53%). Seizures were the most frequent presenting symptom
(77%), followed by focal neurological deficit (26%), mental
changes (15%) and signs of raised intracranial pressure (17%).
The median duration of preoperative symptoms was 3 months
(range: 1 week–157 months). Most tumours were located in the
frontal (51%) and temporal/parietal (45%) lobes and less
frequently in the occipital lobe (4%). The majority of patients
(n¼41) underwent neurosurgery immediately after coming for
medical attention and had their first neuroimaging test.
In six patients, neurosurgical intervention was extended for 36–
150 months. No association was found, using Pearson’s correlation
coefficient, between preoperative interval and proliferation index
or chromosomal status. For this reason all cases were included in
this study.
Neurosurgical procedures consisted of a biopsy in 29 (62%) and
resection in 18 (38%) patients. Radiotherapy was given
immediately postoperative in 28 (60%) patients, delayed in 10
(21%) patients, and nine (19%) patients were still not irradiated at
the last follow-up.
Proliferation index: Ki-67 immunohistochemistry
Paraffin sections (5-mm thick) were preincubated in methanol
with 0.3% H2O2. Tissues known to be negative and positive for
Ki-67 were used as controls. Antigen retrieval was achieved
by incubation with 10mM citrate buffer (pH 6.0) in a
domestic microwave oven at 700W for 10min. The sections were
incubated with the mouse monoclonal antibody MIB-1 directed
against Ki-67 (Immunotech S.A., Marseille, France) at a
1:12 solution in PBS containing 4% normal goat serum
for 60min. Subsequently, biotin-labelled horse anti-mouse
antibody at a 1:200 dilution and avidin–biotin peroxidase
complex (Vector Laboratories, Burlingame, CA, USA) were applied
for 60 and 45min, respectively. Peroxidase activity was detected
using diaminobenzidine in PBS/ imidazol buffer with 0.02%
H2O2. Nuclei were scored for positivity in 500 cells in each sample
in the areas with highest immunopositivity. The mean
proliferation (Ki-67) index was 2.7% (range 0.0–9.2%).
Detection of numerical chromosomal aberrations by in situ
hybridisation (ISH)
In situ hybridisation was performed as described earlier (Hopman
and Ramaekers, 1998). Paraffin sections (5-mm thick) were
deparaffinised and pretreated in 85% formic acid/0.3% H2O2
for 20min. Thereafter the slides were incubated in 1 M
sodium-thiocyanate at 801C for 10min. Subsequently, proteolytic
digestion was performed by 4mgml
 1 pepsin (Sigma Chemical Co,
St Louis, MO, USA) for 10min at 371C in 0.02 M HCl. Then
the slides were fixed in 1% formaldehyde in phosphate-buffered
saline (PBS) for 15min, and rinsed in PBS and double distilled
water.
The biotin-labelled DNA probes used in this study were
specific for the centromeric regions of chromosome 1
(1q12, pUC 1.77) and chromosome 10 (D10Z1), and the alphoid
region of chromosome 7 (p7t1). The probes were hybridised to the
target-DNA in a mixture containing 2 standard saline citrate
(SSC), 60% formamide, 10% dextran sulphate, and 0.2mgml
 1
herring sperm DNA. After denaturation at 801C for 5min, the
slides were incubated overnight at 371C. Subsequently, the slides
were washed twice in 2 SSC/0.05% Tween at 451C, and in
four SSC/0.05% Tween at room temperature. To detect probe
hybridisation, the slides were incubated for 30min at room
temperature with mouse-antibiotin monoclonal antibody, followed
by biotinylated horse-anti-mouse, and finally with the avidin–
biotin–peroxidase complex (Vector Laboratories, Burlingame, CA,
USA). Finally, 0.1 M diaminobenzidine (Sigma) in PBS containing
0.03% H2O2 was applied for visualisation of the peroxides’ activity.
To improve identification of the individual nuclei, bright-field
microscopy was combined with fluorescent nuclear counter-
staining using 4,6-diamino-phenylindol (DAPI, Sigma). The
samples were evaluated with a Leica DMBRE microscope (Leica
Mikroskopie & Systeme GmbH, Wetzlar, Germany). The number
of signals per nucleus was counted in at least 200 nonoverlapping
nuclei. Trisomy/polysomy (gain) was defined as 45% of nuclei
containing three or more signals, and monosomy (loss) as 425%
of nuclei with none or one signal per nucleus. The tumours were
classified as aneusomic when gain or loss of at least one of the
chromosomes was detected. The other A II were classified disomic.
As detected by ISH, 32 (68%) of the tumours showed aneusomy for
one or more of the chromosomes investigated. The most frequent
aberration was aneusomy for chromosome 7 in 31 (66%) of A II.
Aneusomy for chromosome 1 was detected in 24 (51%)
and aneusomy for chromosome 10 in 25 (53%) of the
samples. Monosomy 10 was only detected in two samples (4%),
which also showed trisomy/polysomy 7. The data of the individual
chromosomes are described in detail elsewhere (Wessels et al,
2002).
Statistical analyses
The following factors were considered as possible prognostic
parameters for survival: patient age, sex, presenting symptoms,
preoperative duration of symptoms, tumour location, neurosurgi-
cal procedure, timing of radiotherapy, proliferation index, and
chromosomal status.
The. influence of these factors on survival was tested by
univariate analysis using log-rank tests. Possible prognostic
factors from the univariate analyses with P-values less
than 0.10 (according to recommendation in the literature
(Hosmer and Lemeshow, 2000)) were entered into the multivariate
analyses using a forward stepwise method in order to identify
independent prognostic parameters (Cox, 1972). Univariate
and multivariate associations between factors and survival
were assessed using a Cox regression model. Subsequently,
tumour-related factors were used for analysis in age-stratified
groups.
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yRESULTS
The median survival interval for patients with astrocytoma grade II
as estimated by the Kaplan–Meier method was 90 months (95%
confidence interval 72–108 months). When determining the
influence of age on the period of survival after the first diagnosis
of A II, it becomes obvious that the group aged X35 years at the
time of diagnosis exhibits a significantly shorter survival period as
compared to the 18–34 year-old patient group (Figure 1; log-rank;
P-value¼0.05). Other factors significantly associated with shorter
survival were focal neurological deficit at presentation, prolifera-
tion (Ki-67) index 41%, and aneusomy. Upon multivariate
analysis proliferation index 41%, patient age X35 years, and
aneusomy were independently correlated with shorter survival
(Table 1).
To investigate the interactions between the proliferation index
and aneusomy with age, we analysed the influence of these two
factors on survival stratified for age. When correlating the
proliferation index to survival in the two age groups separately,
it appears that in the group of 18–34-year-old patients, a clearcut
distinction can be made between those with a proliferation index
p1%, showing long-term survival, and those with a proliferation
index 41%, showing more progressive AII (Figure 2A; log-rank;
P-value ¼0.02). Also in the X35-year-old patients, the prolifera-
tion index proved to have additional prognostic value, although
less apparent as compared to the younger group (Figure 2B;
P-value¼0.03).
Using the ISH protocol with probes for chromosomes 1,7, and
10, cases of A II with an apparently normal (disomic) chromo-
somal content can be separated from aneusomic cases. In the
whole group of patients with A II the detection of aneusomy has
additional value in distinguishing between rapid and slow
progressive A II. In the stratified age groups an aberrant
chromosomal constitution is not associated with shorter survival
in both the 18–34-year-old (Figure 3A; P-value¼0.36) and the
X35-year-old (Figure 3B; P-value¼0.09) groups.
However, the combination of a high proliferation index and
aneusomy very accurately identified patients with an unfavourable
outcome in both the 18–34-year-old (Figure 4A; P-value¼0.01)
and the X35-year-old patient groups (Figure 4B; P-value¼0.001).
The combination of both factors reclassified three (27%) of 11
patients of 18–34 years into the group with relatively good
prognosis (compare Figures 4A to 2A). In five of 18 patients in the
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Figure 1 Association between patient age (18–34 vs X35 years) and
survival in A II. Kaplan–Meier, P-value ¼ 0.05, log-rank. ..........
18–34 years (n¼19). ——— X35 years (n¼28).
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Figure 2 High proliferation (Ki-67) index in A II is associated with
shorter survival in (A) patients aged 18–34 (P-value¼0.02) and (B)
patients X35 years (P-value¼0.03). Kaplan–Meier; pooled log-rank test,
P-value¼0.002. .......... Proliferation index p1% (n¼18). ——
Proliferation index 41% (n¼29).
Table 1 Unfavourable prognostic factors for patients with astrocytoma
grade II
Parameter Hazard ratio (95% CI)
a P-value
Univariate analysis
Proliferation index 41% (n¼29) 3.63 (1.22–10.82) 0.02
Focal neurological deficit (n¼13) 2.78 (1.12–6.90) 0.03
Aneusomy (n¼32) 3.29 (0.97–11.20) 0.06
Patient age X35 years (n¼28) 2.52 (0.97–6.58) 0.06
Multivariate analysis
Proliferation index 41% (n¼29) 4.81 (1.50–15.38) 0.01
Patient age X35 years (n¼28) 3.01 (1.13–7.99) 0.03
Aneusomy (n¼32) 3.66 (1.06–12.62) 0.04
aCI¼confidence interval.
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correlated with a more favourable course (compare Figures 4B
to 2B).
Figure 5 illustrates a case of A II, localised in the frontal lobe of a
25-year-old patient with epileptic seizures as the sole manifesta-
tion. The proliferation (Ki-67) index was 4.5% and a high
percentage (35%) of nuclei with trisomy for chromosome 7 was
detected by ISH. Despite the favourable clinical features (young
age, no focal deficit), the patient rapidly progressed to astrocytoma
grade IV, and the survival interval after histological diagnosis was
only 36 months.
DISCUSSION
A ‘wait and see’ policy has been propagated for patients under 35
years of age, suffering from epileptic seizures and radiological
suspicion of astrocytoma grade II (A II) (Vecht, 1993). An
important argument for not performing a stereotactic biopsy in
these patients is that the histological diagnosis of A II does not
alter treatment strategy. In the current study, we demonstrate that
the detection of a high proliferative activity in combination with
chromosomal aberrations identifies a subgroup of young A II
patients with a rapid malignant course.
Our study confirms previous studies of A II showing the
prognostic value of patient age and symptoms at presentation
(Lote et al, 1997; Bauman et al, 1999). In multivariate analyses,
only the age of patients at diagnosis remained significantly
associated with survival as an independent clinical factor, when
comparing patient group under and over 35 years of age. However,
when including biological factors describing the proliferative
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Figure 3 Relation of aneusomy with shorter survival in (A) A II patients
aged 18–34 (P-value¼0.36) and (B) patients X35 years (P-value¼0.09).
Kaplan–Meier; pooled log-rank test, P¼0.05. .......... Disomy
(n¼15). —— Aneusomy (n¼32).
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Figure 4 The combination of both high proliferation (Ki-67) index and
aneusomy is strongly associated with a shorter survival in A II patients (A)
aged 18–34 (P¼0.01) and (B) aged X35 years (P¼0.001). Kaplan–
Meier; pooled log-rank test, Po0.0001...........Proliferation index
p1% or Disomy (n¼26). —— Proliferation index 41% and Aneusomy
(n¼21).
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ycapacity and genomic constitution of the lesion, subgroups of
patients with a significantly shorter survival could be distinguished
within these two separate age groups. In our study, immunostain-
ing for the proliferation marker Ki-67 in over 1% of tumour cells
showed the strongest association with survival of patients with A
II. The proliferation (Ki-67) index has been described to increase
with the grade of astrocytomas, although overlap between grades
exists (Sallinen et al, 1994; Korkolopoulou et al, 1997). The
additional value of the Ki-67 labelling protocol in A II was also
demonstrated in two recent studies, although in these studies, no
stratification for patient age was performed (McKeever et al, 1998;
Heesters et al, 1999). We show a significant correlation of
proliferation (Ki-67) index with survival for patients under 35
years, separating a group of young patients with a high
proliferation index and a prognosis similar to that of patients
435 years. Immunolabelling of lesions from patients X35 years of
age identified a subgroup with a low proliferation index,
correlating with a somewhat better prognosis. In the multivariate
analysis, a proliferation (Ki-67) index 41% proved to be a strong
independent prognosticator. This corroborates with a bromodeox-
yuridine-(BrdU)- proliferation marker analysis of A II that also
showed cell cycle activity in 41% of tumour cells to be associated
with shorter survival (Ito et al, 1994). A possible drawback of the
proliferation (Ki-67) index as prognosticator in A II is reflected by
the wide variation of cutoff levels (between 2 and 10%) used in
different studies (McKeever et al, 1998; Heesters et al, 1999; Fisher
et al, 2002). In our series, the discriminative power of the
proliferation (Ki-67) index diminished when using a higher
cutoff level than 1% (data not shown). These differences in
cutoff levels, among different studies, may be explained by
differences in the immunohistochemical procedures applied, such
as the method of antigen retrieval, the immunolabelling protocol,
and by differences in the scoring criteria of (clustered) Ki-67-
positive cells. Therefore, an additional, but independent prognos-
ticator is needed.
The detection of numerical genomic aberrations has such
additional prognostic value to the proliferation (Ki-67) index.
For astrocytomas of all grades, it appears that certain genetic
changes are associated with an unfavourable clinical course.
Astrocytomas with chromosomal abnormalities as detected by
karyotyping lead to a shorter survival as compared to astro-
cytomas without these abnormalities (Kimmel et al, 1992). An ISH
study showed that monosomy for chromosome 10, harbouring the
tumour suppressor gene PTEN/MMAC1, results in shorter survival
(Cianciulli et al, 2000). However, in these series, the majority of
tumours represented high-grade astrocytoma (grades III and IV).
In A II, the most frequently reported genetic aberration is loss or
mutation of the p53 gene, which, however, shows no association
with clinical course (Kraus et al, 1994; al-Sarraj and Bridges, 1995).
One of the very few additional studies correlating genetic
aberrations and clinical course includes a comparative genomic
hybridisation (CGH) analysis, which showed that A II with rapid
malignant progression exhibit a significantly higher number of
chromosomal aberrations as compared to A II with an indolent
behaviour (Sallinen et al, 1997). However, the sensitivity of this
CGH technique is relatively low due to contamination with
normal/reactive cells, which are often present in A II (Kallioniemi
et al, 1994).
In contrast, the ISH procedure is routinely applicable to
paraffin-embedded samples of central nervous system tumours
(Arnoldus et al, 1992). Our study demonstrates that the
detection of chromosomal aberrations by ISH, using a panel
of probes for chromosomes 1, 7, and 10, offers an extra
independent predictor for survival of patients with A II. After
stratification for age, the presence of chromosomal aberra-
tions alone is not significantly associated with shorter survival,
which may be caused by the small size of both groups. However,
in both age groups, the detection of aneusomy by ISH adds
value to the proliferation index, in that increased proliferation
in the presence of chromosomal aberrations is associated with a
poor prognosis.
A correlation between aneusomy and proliferative activity was
demonstrated in astrocytomas of all grades, containing aneuso-
mies for chromosomes 7 and 10, particularly in Ki-67- positive
cells (Steilen-Gimbel et al, 1996). This suggests that an accumula-
tion of chromosomal aberrations in proliferating cells plays an
important role in the early stages of astrocytoma progression. This
also suggests that the combination of both these parameters is
therefore very useful in identifying A II with a rapidly malignant
clinical course.
Although imaging studies were used as adjunct to histology, A
III/IV may also present as nonenhancing lesions (Chamberlain
et al, 1988). Therefore, one could argue that in the stereotactic
specimen, sampling error from high-grade astrocytomas may have
biased the results. This is contradicted, however, by the relatively
long median survival of 90 months, also compared to other A II
studies (Leighton et al, 1997; McCormack et al, 1992). Another
argument against underscoring of the tumours is given by the fact
that only one of the biopsy specimens exhibited monosomy 10,
which is characteristic at low-grade areas in high-grade astro-
cytomas (Cheng et al, 1999).
The additional value of genetic and biological parameters to the
current histological WHO classification was also seen in the three
gemistocytic variants of A II. Previous studies suggest that A II
Figure 5 Astocytoma grade II in a patient aged 25 years with a high
proliferation (Ki-67) index (A), and frequent nuclei with trisomy for
chromosome 7, detected by ISH (B). Counter-staining with DAPI in (B).
Magnifications 800.
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more similar manner to A III (Krouwer et al, 1991). Although two
of our gemistocytic samples contained lower percentages of
gemistocytes, the increased proliferation activity and the presence
of aneusomy in all three samples was associated with a relatively
short survival (range 41–43 months).
We postulate that identification of subtypes of astrocytomas
on the basis of genetic and biological factors has additional
prognostic value to the current histological classification. Tissue
should be obtained in all patients with A II in order to assess the
proliferation activity and, if possible, the presence of trisomy for
chromosome 7. In the future, these markers may help in
optimising treatment strategy, in particular in young patients with
astrocytoma grade II, for whom optimal treatment is now
controversial.
ACKNOWLEDGEMENTS
We thank M Pijls, A Ruland, and J Smeets, Department of
Pathology, University Hospital Maastricht, for their technical
assistance, and Dr P Koehler, neurologist, and Dr M Nap and Dr P
Theunissen, pathologists, Atrium hospital Heerlen, for contribut-
ing clinical data and tissue material.
REFERENCES
al-Sarraj S, Bridges LR (1995) p53 immunoreactivity in astrocytomas and
its relationship to survival. Br J Neurosurg 9: 143–149
Arienti VM, Botturi A, Boiardi A, Broggi G, Collice M, Fariselli L, Zanni D,
Botturi M (2001) Adult brain low-grade astrocytomas: survival after
surgery and radiotherapy. Neurol Sci 22: 233–238
Arnoldus EP, Wolters LBT, Voormolen JHC, van Duinen SG, Raap AK, van
der Ploeg M, Peters ACB (1992) Interphase cytogenetics: a new tool for
the study of genetic changes in brain tumors. J Neurosurg 76: 997–1003
Bauman G, Lote K, Larson D, Stalpers L, Leighton C, Fisher B, Wara W,
MacDonald D, Stitt L, Cairncross JG (1999) Pretreatment factors predict
overall survival for patients with low-grade glioma: a recursive
partitioning analysis. Int J Radiat Oncol Biol Phys 45: 923–929
Berger MS, Deliganis AV, Dobbins J, Keles GE (1994) The effect of extent of
resection on recurrence in patients with low grade cerebral hemisphere
gliomas. Cancer 74: 1784–1791
Chamberlain MC, Murovic JA, Levin VA (1988) Absence of contrast
enhancement on CT brain scans of patients with supratentorial
malignant gliomas. Neurology 38: 1371–1374
Cheng Y, Ng HK, Ding M, Zhang SF, Pang JC, Lo KW (1999) Molecular
analysis of microdissected de novo glioblastomas and paired astrocytic
tumors. J Neuropathol Exp Neurol 58: 120–128
Cianciulli AM, Morace E, Coletta AM, Occhipinti E, Gandolfo GM,
Leonardo G, Carapella CM (2000) Investigation of genetic alterations
associated with development and adverse outcome in patients with
astrocytic tumor. J Neurooncol 48: 95–101
Cox D (1972) Regression model and life tables. J R Stat Soc Ser B 34:
187–229
Fisher BJ, Naumova E, Leighton CC, Naumov GN, Kerklviet N, Fortin D,
Macdonald DR, Cairncross JG, Bauman GS, Stitt L (2002) Ki-67: a
prognostic factor for low-grade glioma? Int J Radiat Oncol Biol Phys 52:
996–1001
Heesters MAAM, Koudstaal J, Go KG, Molenaar WM (1999) Analysis of
proliferation and apoptosis in brain gliomas: prognostic and clinical
value. J Neurooncol 44: 255–266
Hopman AHN, Ramaekers FCS (1998) Processing and staining of cell and
tissue material for interphase cytogenetics. In Current protocols in
cytometry, Robinson P (ed). New York: John Wiley & Sons, Inc
(CHAPTER 8.5.1-8.5.2)
Hosmer DW, Lemeshow S (2000) Applied Logistic Regression. New York
John Wiley & Sons
Ito S, Chandler KL, Prados MD, Lamborn K, Wynne J, Malec M, Wilson C,
Davis R, Hoshino T (1994) Proliferative potential and prognostic
evaluation of low-grade astrocytomas. J Neurooncol 19: 1–9
Kallioniemi OP, Kallioniemi A, Piper J, Isola J, Waldman FM, Gray JW,
Pinkel D (1994) Optimizing comparative genomic hybridization for
analysis of DNA sequence copy number changes in solid tumors. Genes
Chromosomes Cancer 10: 231–243
Karim ABMF, Afra D, Cornu P, Bleehan N, Schraub S, De Witte O, Darcel F,
Stenning S, Pierart M, van Glabbeke M (2002) Randomized trial on the
efficacy of radiotherapy for cerebral low-grade glioma in the adult:
European Organization for Research and Treatment of Cancer Study
22845 with the Medical Research Council study BRO4: an interim
analysis. Int J Radiat Oncol Biol Phys 52: 316–324
Karim ABMF, Maat B, Hatlevoll R, Menten J, Rutten EHJ, Thomas DGT,
Mascarenhas F, Horiot JC, Parvinen LM, van Reijn M, Jager JJ, Fabrini
MG, van Alphen AM, Hamers HP, Gaspar L, Noordman E, Pierart M, van
Glabbeke M (1996) A randomized trial on dose–response in radiation
therapy of low-grade cerebral glioma: European Organization for
Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat
Oncol Biol Phys 36: 549–556
Kimmel DW, O’Fallon JR, Scheithauer BW, Kelly PJ, Dewald GW, Jenkins
RB (1992) Prognostic value of cytogenetic analysis in human cerebral
astrocytomas. Ann Neurol 31: 534–542
Korkolopoulou P, Christodoulou P, Kouzelis K, Hadjiyannakis M, Priftis A,
Stamoulis G, Seretis A, Thomas-Tsagli E (1997) MDM2 and p53
expression in gliomas: a multivariate survival analysis including
proliferation markers and epidermal growth factor receptor. Br J Cancer
75: 1269–1278
Kleihues P, Cavenee WK (2000) Pathology and Genetics of Tumors of the
Nervous Sytem. IARC press: Lyon
Kraus JA, Bolln C, Wolf HK, Neumann J, Kindermann D, Fimmers R, Forster
F, Baumann A, Schlegel U (1994) TP53 alterations and clinical outcome in
low grade astrocytomas. Genes Chromosomes Cancer 10: 143–149
Krouwer HG, Davis RL, Silver P, Prados MD (1991) Gemistocytic
astrocytomas: a reappraisal. J Neurosurg 74: 399–406
Leighton C, Fisher B, Bauman G, Depiero S, Stitt L, MacDonald D,
Cairncross G (1997) Supratentorial low-grade glioma in adults: an
analysis of prognostic factors and timing of radiation. J Clin Oncol 15:
1294–1301
Lote K, Egeland T, Hager B, Stenwig B, Skullerud K, Berg-Johnsen J, Storm-
Mathisen I, Hirschberg H (1997) Survival, prognostic factors, and
therapeutic efficacy in low-grade glioma: a retrospective study in 379
patients. J Clin Oncol 15: 3129–3140
McCormack BM, Miller DC, Budzilovich GN, Voorhees GJ, Ransohoff J
(1992) Treatment and survival of low-grade astrocytoma in adults – 1977
– 1988. Neurosurgery 31: 636–642
McKeever PE, Strawderman MS, Yamini B, Mikhail AA, Blaivas M (1998)
MIB-1 proliferation index predicts survival among patients with grade II
astrocytoma. J Neuropathol Exp Neurol 57: 931–936
Recht LD, Lew R, Smith TW (1992) Suspected low-grade glioma: is
deferring treatment safe? Ann Neurol 31: 431–436
Sallinen PK, Haapasalo HK, Visakorpi T, Helen PT, Rantala IS, Isola JJ,
Helin HJ (1994) Prognostication of astrocytoma patient survival by Ki-67
(MIB-1), PCNA, and S-phase fraction using archival paraffin-embedded
samples. J Pathol 174: 275–282
Sallinen SL, Sallinen P, Haapasalo H, Kononen J, Karhu R, Helen P,
Isola J (1997) Accumulation of genetic changes is associated
with poor prognosis in grade II astrocytomas. Am J Pathol 151:
1799–1807
Shaw EG, Arusell R, Scheithauer BW, O’Fallon JR, O’Neill B, Dinapoli R,
Nelson D, Earle JD, Jones C, Cascino T, Nichols D, Ivnik R, Hellman R,
Curran W, Abrams R (2002) Prospective randomized trial of low- versus
high-dose radiation therapy in adults with supratentorial low-grade
glioma: initial report of a North Central Cancer Treatment Group/
Radiation Therapy Oncology Group/Eastern Cooperative Oncology
Group study. J Clin Oncol 20: 2267–2276
Shaw EG, Daumas-Duport C, Scheithauer BW, Gilbertson DT, O’Fallon JR,
Earle JD, Laws ER, Okazaki H (1989) Radiation therapy in the
management of low-grade supratentorial astrocytomas. J Neurosurg 70:
853–861
Steilen-Gimbel H, Henn W, Kolles H, Moringlane JR, Feiden W, Steudel WI,
Zang KD (1996) Early proliferation enhancement by monosomy 10 and
Prognostic factors in astrocytoma grade II
PH Wessels et al
133
British Journal of Cancer (2003) 89(1), 128–134 & 2003 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yintratumor heterogeneity in malignant human gliomas as revealed by
smear preparations from biopsies. Genes Chromosomes Cancer 16:
180–184
Vecht CJ (1993) Effect of age on treatment decisions in low-grade glioma. J
Neurol Neurosurg Psychiatry 56: 1259–1264
Wessels PH, Twijnstra A, Kessels AGH, Krijne-Kubat B, Theunissen PH,
Ummelen MIJ, Ramaekers FCS, Hopman AHN (2002) Gain of chromo-
some 7 as detected by in situ hybridization (ISH) strongly correlates with
shorter survival in astrocytoma grade 2. Genes Chromosomes Cancer 33:
279–284
Prognostic factors in astrocytoma grade II
PH Wessels et al
134
British Journal of Cancer (2003) 89(1), 128–134 & 2003 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y